| DTGCX | PRGTX | DTGCX / PRGTX | |
| Total Expense Ratio | 1.97 | 0.93 | 212% |
| Annual Report Gross Expense Ratio | 1.97 | 0.93 | 212% |
| Fund Existence | 27 years | 26 years | - |
| Gain YTD | 20.420 | 26.026 | 78% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 2500 | 40% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 518M | 7.84B | 7% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 4.51 | 40.82 | 11% |
| Returns for 3 years | 51.07 | 129.81 | 39% |
| Returns for 5 years | -18.42 | 4.33 | -425% |
| Returns for 10 years | 6.04 | 134.81 | 4% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SHPAX | 22.81 | 0.16 | +0.71% |
| Saratoga Health & Biotechnology A | |||
| FDTZX | 27.05 | 0.01 | +0.04% |
| Fidelity Advisor Capital Development M | |||
| KGDIX | 39.05 | -0.16 | -0.41% |
| DWS Global Small Cap Inst | |||
| SCMGX | 22.15 | -0.13 | -0.58% |
| Sands Capital Global Growth Inst | |||
| TEMPX | 11.38 | -0.25 | -2.15% |
| Nuveen Emerging Markets Eq Prem | |||